# A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Study · id `cardio:ct-nct04605991` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04605991](<https://clinicaltrials.gov/study/NCT04605991>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04605991

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.

## Technical summary

Registry record NCT04605991. Allocation not applicable; no masking; primary purpose treatment. Start 2020-11-04 (actual); primary completion 2022-02-04 (actual). Results posted on 2023-03-03.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 187 participants (enrolled count; ClinicalTrials.gov record NCT04605991, source copy `cardio:ctgov-nct04605991-2023-03-03`, retrieved 2026-10-26)
- Started: 2020-11-04 (actual) (ClinicalTrials.gov record NCT04605991, source copy `cardio:ctgov-nct04605991-2023-03-03`, retrieved 2026-10-26)
- Primary completion: 2022-02-04 (actual) (ClinicalTrials.gov record NCT04605991, source copy `cardio:ctgov-nct04605991-2023-03-03`, retrieved 2026-10-26)
- Completion: 2022-02-04 (actual) (ClinicalTrials.gov record NCT04605991, source copy `cardio:ctgov-nct04605991-2023-03-03`, retrieved 2026-10-26)
- Results first posted: 2023-03-03 (ClinicalTrials.gov record NCT04605991, source copy `cardio:ctgov-nct04605991-2023-03-03`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT04605991, source copy `cardio:ctgov-nct04605991-2023-03-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04605991-2023-03-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
- Condition: Type 2 Diabetes
- Intervention (Drug): LY900014
- Intervention (Drug): Insulin Glargine
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 4d6ce16258c64db236e30d8cdf4e275acfae0a12f8df808b997563602bbcca52
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
